Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
$34.49
$34.46
$10.09
$37.00
$2.26B1.761.71 million shsN/A
Aphria Inc. stock logo
APHA
Aphria
$15.38
$15.48
$2.78
$32.29
$4.87B2.6721.83 million shsN/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
$6.96
+1.5%
$6.25
$3.33
$7.05
$1.32B1.321.84 million shs1.84 million shs
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$22.80
+2.7%
$23.81
$20.84
$34.28
$2.37B0.481.47 million shs795,534 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
0.00%0.00%0.00%0.00%0.00%
Aphria Inc. stock logo
APHA
Aphria
0.00%0.00%0.00%0.00%0.00%
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
+1.70%+5.29%+6.60%+20.86%+63.06%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-1.20%-1.99%-10.26%+2.54%-0.09%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Aphria Inc. stock logo
APHA
Aphria
N/AN/AN/AN/AN/AN/AN/AN/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
2.597 of 5 stars
1.31.00.04.93.81.70.6
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
4.8188 of 5 stars
3.51.00.04.53.03.33.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
N/AN/AN/AN/A
Aphria Inc. stock logo
APHA
Aphria
N/AN/AN/AN/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
2.50
Moderate Buy$7.507.76% Upside
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
3.00
Buy$39.3072.37% Upside

Current Analyst Ratings

Latest BKD, PRY, APHA, CORT, and AIMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00
4/9/2024
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$9.00
2/16/2024
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$36.00 ➝ $42.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
N/AN/AN/AN/A$1.66 per shareN/A
Aphria Inc. stock logo
APHA
Aphria
$405.96M12.00$0.09 per share166.43$4.80 per share3.20
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
$3.02B0.44$0.88 per share7.91$2.15 per share3.24
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$482.38M4.92$0.97 per share23.47$4.92 per share4.63

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/A
Aphria Inc. stock logo
APHA
Aphria
-$63.21M-$0.06N/A219.71N/A-36.10%-2.30%-1.66%N/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$189.01M-$0.84N/AN/AN/A-6.27%-44.01%-3.75%5/7/2024 (Confirmed)
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$106.14M$0.9524.0017.14N/A21.86%21.98%17.89%5/1/2024 (Confirmed)

Latest BKD, PRY, APHA, CORT, and AIMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$0.17N/A+$0.17N/AN/AN/A  
5/1/2024N/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.18N/A-$0.18N/AN/AN/A  
2/20/2024Q4 2023
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
-$0.19-$0.40-$0.21-$0.40N/A$754.48 million
2/15/2024Q4 2023
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.25$0.28+$0.03$0.28$129.27 million$135.41 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
N/AN/AN/AN/AN/A
Aphria Inc. stock logo
APHA
Aphria
N/AN/AN/AN/AN/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
N/AN/AN/AN/AN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
0.73
7.53
7.40
Aphria Inc. stock logo
APHA
Aphria
0.25
2.36
1.17
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
9.40
0.80
0.80
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
4.39
4.31

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
74.47%
Aphria Inc. stock logo
APHA
Aphria
10.30%
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
N/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%

Insider Ownership

CompanyInsider Ownership
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
13.75%
Aphria Inc. stock logo
APHA
Aphria
N/A
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
1.50%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
19.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
22865.45 millionN/AOptionable
Aphria Inc. stock logo
APHA
Aphria
1,200316.80 millionN/AOptionable
Brookdale Senior Living Inc. stock logo
BKD
Brookdale Senior Living
25,200189.34 million186.50 millionOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
352104.08 million83.48 millionOptionable

BKD, PRY, APHA, CORT, and AIMT Headlines

SourceHeadline
Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action SettlementLevi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com - April 25 at 12:30 PM
Corcept Therapeutics (CORT) Scheduled to Post Earnings on WednesdayCorcept Therapeutics (CORT) Scheduled to Post Earnings on Wednesday
marketbeat.com - April 25 at 11:47 AM
Corcept Therapeutics (NASDAQ:CORT) Raised to "Strong-Buy" at StockNews.comCorcept Therapeutics (NASDAQ:CORT) Raised to "Strong-Buy" at StockNews.com
americanbankingnews.com - April 25 at 2:20 AM
Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.3%Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.3%
marketbeat.com - April 24 at 4:21 PM
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference CallCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
globenewswire.com - April 24 at 4:05 PM
Corcept Therapeutics gets grant for treating antipsychotic-induced weight gain with miricorilantCorcept Therapeutics gets grant for treating antipsychotic-induced weight gain with miricorilant
pharmaceutical-technology.com - April 24 at 10:41 AM
Corcept Therapeutics (NASDAQ:CORT) Receives Buy Rating from HC WainwrightCorcept Therapeutics (NASDAQ:CORT) Receives Buy Rating from HC Wainwright
americanbankingnews.com - April 24 at 4:42 AM
Promising Clinical Outcomes and Market Potential: Buy Rating for Corcept’s RelacorilantPromising Clinical Outcomes and Market Potential: Buy Rating for Corcept’s Relacorilant
markets.businessinsider.com - April 23 at 7:28 PM
Corcept Therapeutics (NASDAQ:CORT) Trading Up 7.5%Corcept Therapeutics (NASDAQ:CORT) Trading Up 7.5%
marketbeat.com - April 23 at 3:43 PM
Corcept Therapeutics (NASDAQ:CORT) Given Buy Rating at HC WainwrightCorcept Therapeutics (NASDAQ:CORT) Given Buy Rating at HC Wainwright
marketbeat.com - April 23 at 1:49 PM
Corcept (CORT) Posts Positive Data From Cushings Syndrome StudyCorcept (CORT) Posts Positive Data From Cushing's Syndrome Study
zacks.com - April 23 at 1:16 PM
Corcept Therapeutics Target of Unusually Large Options Trading (NASDAQ:CORT)Corcept Therapeutics Target of Unusually Large Options Trading (NASDAQ:CORT)
americanbankingnews.com - April 23 at 1:06 AM
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This QuarterMid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter
msn.com - April 22 at 3:34 PM
Corcept falls after phase 3 results on Cushings candidate doesnt include some dataCorcept falls after phase 3 results on Cushing's candidate doesn't include some data
msn.com - April 22 at 3:34 PM
Corcept Therapeutics (NASDAQ:CORT) Sets New 52-Week Low at $20.84Corcept Therapeutics (NASDAQ:CORT) Sets New 52-Week Low at $20.84
marketbeat.com - April 22 at 11:59 AM
Corcept Therapeutics Sees Unusually Large Options Volume (NASDAQ:CORT)Corcept Therapeutics Sees Unusually Large Options Volume (NASDAQ:CORT)
marketbeat.com - April 22 at 11:38 AM
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s SyndromeCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
finance.yahoo.com - April 22 at 10:33 AM
45,200 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Acquired by Louisiana State Employees Retirement System45,200 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Acquired by Louisiana State Employees Retirement System
marketbeat.com - April 21 at 5:08 AM
Cerity Partners LLC Has $2.41 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Cerity Partners LLC Has $2.41 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)
marketbeat.com - April 19 at 5:13 AM
Q3 2025 Earnings Estimate for Corcept Therapeutics Incorporated (NASDAQ:CORT) Issued By Zacks ResearchQ3 2025 Earnings Estimate for Corcept Therapeutics Incorporated (NASDAQ:CORT) Issued By Zacks Research
americanbankingnews.com - April 19 at 3:02 AM
Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action SettlementLevi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com - April 18 at 12:15 PM
Zacks Research Weighs in on Corcept Therapeutics Incorporateds Q3 2025 Earnings (NASDAQ:CORT)Zacks Research Weighs in on Corcept Therapeutics Incorporated's Q3 2025 Earnings (NASDAQ:CORT)
marketbeat.com - April 18 at 6:31 AM
Corcept Therapeutics (NASDAQ:CORT) Downgraded to "Buy" at StockNews.comCorcept Therapeutics (NASDAQ:CORT) Downgraded to "Buy" at StockNews.com
americanbankingnews.com - April 18 at 6:30 AM
Corcept Therapeutics Incorporated (NASDAQ:CORT) Short Interest Up 5.5% in MarchCorcept Therapeutics Incorporated (NASDAQ:CORT) Short Interest Up 5.5% in March
americanbankingnews.com - April 18 at 5:54 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Aimmune Therapeutics logo

Aimmune Therapeutics

NASDAQ:AIMT
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Aphria logo

Aphria

NASDAQ:APHA
Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.
Brookdale Senior Living logo

Brookdale Senior Living

NYSE:BKD
Brookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.
Corcept Therapeutics logo

Corcept Therapeutics

NASDAQ:CORT
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.